Aptose Biosciences Inc.
APS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.59M | -6.95M | -7.25M | -9.64M | -11.96M |
| Total Depreciation and Amortization | 97.00K | 96.00K | 102.00K | 109.00K | 110.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -599.00K | 2.00K | 283.00K | 846.00K | 490.00K |
| Change in Net Operating Assets | -5.97M | -3.52M | 1.09M | -3.08M | 2.10M |
| Cash from Operations | -8.06M | -10.38M | -5.78M | -11.76M | -9.26M |
| Capital Expenditure | -5.00K | -- | -- | -- | 0.00 |
| Sale of Property, Plant, and Equipment | 5.00K | -- | 17.00K | 1.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 1.99M | -1.99M | 1.94M |
| Cash from Investing | 0.00 | -- | 2.01M | -1.99M | 1.94M |
| Total Debt Issued | 10.00M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 10.01M | 4.93M | 11.85M | 844.00K |
| Repurchase of Common Stock | -3.35M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 156.00K | -- | -177.00K | -- | 10.00K |
| Cash from Financing | 6.81M | 10.01M | 4.75M | 11.85M | 854.00K |
| Foreign Exchange rate Adjustments | -- | -- | -1.00K | 1.00K | -1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.26M | -368.00K | 984.00K | -1.91M | -6.47M |